These results suggest the FilC/PD-1 recombinant virus as a possible selective oncolytic virotherapy for HCC, as it replicates efficiently in both tumorigenic and non-tumorigenic cells with a markedly reduced replication rate in non-cancerous hepatocytes (Table 2). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.